Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00594308 · OUTCOME

Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).

In-Vivo Activated T-Cell Depletion to Prevent GVHD · Source last updated 2014-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
until 30 days after stem cell transplant

Analysis population: ITT population. All patient that received study drug

Groups in this outcome

Basiliximab 20 mg

All patients that received Basiliximab 20 mg monoclonal therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Basiliximab 20 mg10

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Basiliximab 20 mg10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
groups
  1. description
    All patients that received Basiliximab 20 mg monoclonal therapy
    id
    OG000
    title
    Basiliximab 20 mg
param Type
NUMBER
population Description
ITT population. All patient that received study drug
time Frame
until 30 days after stem cell transplant
title
Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice